Form 4 for SMMT Summit Therapeutics Inc.
Accepted 2024-03-27 00:00:00 ET · period of report 2024-03-26 · accession 0001599298-24-000046 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2024-03-27 | 2024-03-26 | SMMT | Dhingra Ankur | CFO | P - Purchase | $3.75 | +100.0K | 355.0K | +39% | +$375.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-26 | P | A | 100,000 | $3.75 | 354,958 | I By Dhingra Family Revocable Trust | — | — | (F1) The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.74 to $3.76 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |